The Histogen Inc (NASDAQ: HSTO) stock price rallied 33.4% after revealing that it had been issued a U.S. patent covering CTS-2090 Methods of Use. The US Patent and Trademark Office (USPTO) issued Histogen with US Patent No. 11,579,703, titled “Caspase Inhibitors and Methods of Use Thereof.”
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
Investors cheered the patent award, which provides comprehensive coverage for Histogen’s portfolio of highly selective and orally active anti-inflammatory caspase inhibitors, including CTS-2090. The patent also states that CTS-2090 has demonstrated potent oral activity in a well-characterized model of ulcerative colitis.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Tickmill Regulated by the FCA – Read our Review
- Admirals (Admiral Markets) More than 4500 stocks & ETFs available – Read our Review
- Spreadex Spreadex has been around for a long time – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Furthermore, CTS-2090 also generated statistically significant protection against inflammation-driven damage to the lining of the gastrointestinal tract and protected patients against body weight loss.
While CTS-2090 is regarded as a potent anti-inflammatory drug, it had no effect in well-accepted cellular and in vivo models of apoptosis. The results confirmed its high selectivity as an anti-inflammatory caspase inhibitor.
Histogen is a clinical-stage therapeutics firm specialising in developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors, which can protect the body’s natural processes and restore immune function.
Over 1.7 million Histogen shares had changed hands as retail investors bought them following the patent award.
Alfred Spada, Hisogen’s EVP and Chief Scientific Officer, said: “We are pleased that this important patent has issued. It builds upon Histogen’s growing proprietary caspase inhibitor portfolio that includes the US patent No. 11,447,497 issued in September of 2022. This previously issued patent discloses a broad class of novel pan-caspase inhibitors with unique chemical properties.”
He added:
“In addition to these two important patents to support our expanding pipeline, we are also evaluating the potential use of our clinical-stage pan-caspase inhibitor, emricasan, in acute bacterial skin infections, including those related to methicillin-resistant staph aureus (MRSA).”
*This is not investment advice.
The Histogen stock price.
The Histogen stock price rallied 33.36% to trade at $1.15, from Thursday’s closing price of $0.86.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.